Abeona director sells 13,500 shares at $5.23

Abeona Therapeutics Inc. director Mark Alvino reported selling 13,500 shares of the company’s common stock on 01/21/2026.

Accepted by SEC EDGAR 01/21/2026 - 04:30 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Abeona Therapeutics Inc. director Mark Alvino reported selling 13,500 shares of the company’s common stock on 01/21/2026. The shares were sold at a weighted average price of $5.2277 per share, with individual trade prices ranging from $5.21 to $5.235. After this transaction, he beneficially owns 48,752 common shares directly.

The filing notes that detailed price and size information for each individual trade within the reported price range is available upon request from the company, any security holder, or the SEC staff.

Insider Trade Summary

Net Seller: 13,500 shares

Net Sell 1 txn

Insider Alvino Mark

Role Director

Sold 13,500 shs ($71K)

Share of Position Sold 21.7%

Type	Security	Shares	Price	Value
Sale	Common Stock	13,500	$5.2277	$71K

Holdings After Transaction: Common Stock — 48,752 shares (Direct)

Holdings Before and After: Common Stock, 62,252 to 48,752 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.21 to $5.235 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Abeona Therapeutics (ABEO) report for director Mark Alvino?

The filing shows that director Mark Alvino sold 13,500 shares of Abeona Therapeutics common stock on 01/21/2026.

At what price did Mark Alvino sell Abeona Therapeutics (ABEO) shares?

The sale was reported at a weighted average price of $5.2277 per share, with individual trades executed between $5.21 and $5.235.

How many Abeona Therapeutics (ABEO) shares does Mark Alvino hold after the reported sale?

After the transaction, Mark Alvino beneficially owns 48,752 shares of Abeona Therapeutics common stock directly.

What does the weighted average price mean in this Abeona Therapeutics (ABEO) Form 4?

The weighted average price of $5.2277 means the 13,500 shares were sold in multiple trades, each within the $5.21 to $5.235 range, averaged by share volume.

Can investors obtain more detailed trade data for this Abeona Therapeutics (ABEO) insider sale?

Yes. The reporting person undertakes to provide full information on the number of shares sold at each separate price to the issuer, any security holder, or SEC staff upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alvino Mark

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/21/2026		S		13,500	D	$5.2277(1)	48,752	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.21 to $5.235 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Mark Alvino	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.